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ABSTRACT VirF, an AraC-like activator, is required to trigger a regulatory cascade that initiates the invasive program of Shigella
spp., the etiological agents of bacillary dysentery in humans. VirF expression is activated upon entry into the host and depends
onmany environmental signals. Here, we show that the virFmRNA is translated into two proteins, the major form, VirF30
(30 kDa), and the shorter VirF21 (21 kDa), lacking the N-terminal segment. By site-specific mutagenesis and toeprint analysis, we
identified the translation start sites of VirF30 and VirF21 and showed that the two different forms of VirF arise from differential
translation. Interestingly, in vitro and in vivo translation experiments showed that VirF21 is also translated from a leaderless
mRNA (llmRNA) whose 5= end is at position309/310, only 1 or 2 nucleotides upstream of the ATG84 start codon of VirF21.
The llmRNA is transcribed from a gene-internal promoter, which we identified here. Functional analysis revealed that while
VirF30 is responsible for activation of the virulence system, VirF21 negatively autoregulates virF expression itself. Since VirF21
modulates the intracellular VirF levels, this suggests that transcription of the llmRNAmight occur when the onset of the viru-
lence program is not required. We speculate that environmental cues, like stress conditions, may promote changes in virFmRNA
transcription and preferential translation of llmRNA.
IMPORTANCE Shigella spp. are a major cause of dysentery in humans. In bacteria of this genus, the activation of the invasive pro-
gram involves a multitude of signals that act on all layers of the gene regulatory hierarchy. By controlling the essential genes for
host cell invasion, VirF is the key regulator of the switch from the noninvasive to the invasive phenotype. Here, we show that the
Shigella virF gene encodes two proteins of different sizes, VirF30 and VirF21, that are functionally distinct. The major form,
VirF30, activates the genes necessary for virulence, whereas the minor VirF21, which shares the C-terminal two-thirds of VirF30,
negatively autoregulates virF expression itself. VirF21 is transcribed from a newly identified gene-internal promoter and, more-
over, is translated from an unusual leaderless mRNA. The identification of a new player in regulation adds complexity to the reg-
ulation of the Shigella invasive process andmay help development of new therapies for shigellosis.
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Shigella spp. are highly adapted human pathogens that causebacillary dysentery (1). The sophisticated infectious strat-
egy of Shigella depends on the capacity to invade, disrupt, and
cause inflammatory destruction of the intestinal epithelial bar-
rier (2, 3). Activation of the invasive program is exceptionally
complex and involves many signals affecting gene regulation at
different levels. A key factor is VirF, an AraC-like transcription
factor (TF) whose expression is activated as Shigella bacteria
sense entry into the host environment (4, 5). In a cascade
model, VirF triggers activation of the virB and icsA genes. IcsA
affects bacterial intracellular spreading, and VirB promotes ex-
pression of several virulence genes, including those encoding a
type III secretion system (T3SS), its effectors, and the last reg-
ulator of the cascade, MxiE (6, 7). Interestingly, MxiE, another
AraC-like TF, appears to rely on high-level transcriptional slip-
page to generate its reading frame from two separate open
reading frames (ORFs) (8). The genes virF, icsA, virB, and
those controlled by VirB are located on a virulence plasmid
(pINV) and are silenced outside the human host (9). At low
temperatures, the nucleoid-associated protein H-NS represses
transcription of the virulence genes (5). In a temperature-
dependent manner, H-NS interacts with two sites within the
virF promoter, spaced by an intrinsically curved DNA region,
to prevent access of RNA polymerase (5, 10, 11). At a permis-
sive temperature (37°C), reduced DNA curvature counteracts
H-NS binding (4, 12) and unmasks a binding site for the nu-
cleoid protein FIS to activate virF transcription (13). VirF then
relieves H-NS-mediated repression of virB and icsA and di-
rectly stimulates transcription (14, 15). By binding upstream of
the virF promoter between two H-NS sites, VirB also counter-
acts H-NS-dependent repression of virF transcription (16). Ex-
pression of virF is further modulated by integration host factor
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(IHF) (17) and other environmental factors, such as pH and
osmolarity (7), and is affected by tRNA modifications (18).
The relevance of virF activation for the invasive program is
further supported by posttranscriptional regulation of icsA. RnaG
is a cis-encoded antisense RNA that promotes premature termi-
nation of the icsAmRNA (19). VirF binds the RnaG promoter and
decreases rnaG expression (14). Thus, VirF plays a dual role: (i) it
relieves H-NS-mediated repression to activate icsA transcription,
and (ii) it represses RnaG transcription, thus increasing the level
of icsA mRNA (14). VirF also globally activates the expression of
chromosomal genes in both Shigella and Escherichia coli. In par-
ticular, VirF appears to play a role in shaping the Shigella tran-
scriptional program to better match the requirements of an effec-
tive intracellular life (20–22).
Like other members of the AraC family of transcriptional reg-
ulators, VirF has a conserved, carboxy-terminalDNA-binding do-
main with two helix-turn-helix (HTH)motifs. AraC-like proteins
are typically insoluble and, accordingly, problems with VirF puri-
fication have hampered biochemical studies (23).Mutagenesis ex-
periments indicated that the N-terminal domain of VirF pro-
motes dimerization while C-terminal HTH2 motif mutants are
nonfunctional (24).
While attempting a thorough characterization of VirF, we
found that the virF mRNA (R1) is subject to differential transla-
tion, giving rise to two forms ofVirF. VirF30 activates the virulence
system and some chromosomal genes, whereas VirF21 exerts neg-
ative feedback control on virF expression itself.
Moreover, we identified a second virFmRNA species (R2)with
a 5= end at position nucleotide (nt) 309/310. This leaderless
yet translation-competent mRNA is transcribed from a gene-
internal promoter. Possible implications in an interplay between
environmental sensing and virulence gene expression are dis-
cussed.
RESULTS
The virF gene encodes two independently translated proteins,
VirF30 and VirF21. Earlier experiments on E. coli minicells carry-
ing the virF gene on recombinant plasmids from Shigella flexneri
and Shigella sonnei indicated two main VirF protein forms of
about 30 and 21 kDa and a minor form of 27 kDa (25, 26). The
significance of the 27- and 21-kDa forms remained unclear, and it
seemed possible that they were degradation products of full-
length VirF (27). To analyze which VirF forms are present in Shi-
gella, a 3FLAG tag sequence was inserted at the 3= end of the
S. flexneri M90T virF ORF. Western blot analysis (Fig. 1A) con-
firmed that two VirF proteins, VirF30 (30 kDa) and VirF21
(21 kDa), are expressed by S. flexneri. The 27-kDa form was not
detected.
The sequence of the virF gene contains three putative start
codons, all in the same frame, for VirF30 and an internal ATG
codon, consistent with independent translation of VirF21 (25).
Thus, we determined at which ATG codons VirF30 and VirF21
translation initiates. In the absence of a recognizable Shine-
Dalgarno (SD) sequence upstream, prediction of the ATG encod-
ing the N-terminal methionine of VirF30 was difficult. Thus, each
of the ATG codons (codons 1, 2, and 4; codon 3 encodes Asp)
(Fig. 1B)was tested for translation initiation activity by using plas-
mids carrying the virF promoter followed by a virF-lacZ transla-
tional fusion. Plasmid pFL-4A is fused in frame after the fourth
virF codon (third Met codon), and pFL-1A is fused after the first
ATG (Fig. 2A). -Galactosidase activities indicated that the con-
struct with all three ATGs has 5-fold-higher activity than the
one fused after ATG1. Thus, ATG2 and/or ATG4 appear to be
required for high translation of VirF30, and ATG1 gives a minor
contribution. ATG4, which has a short upstream SD-like (GAA)
sequence, was tested by introducing an ATG4¡ GGG (Gly) mu-
tation into pFL-4A. This plasmid, pFL-M4G, in which ATG1 and
ATG2 are still present, gave very low reporter gene activity
(Fig. 2A), suggesting ATG4 as the main VirF30 start codon. West-
ern blot analysis supported this. VirF30 was produced only from
the wild-type (wt) virF gene, but not when ATG4 had mutated
(Fig. 2B, cf. pMYSH6504 and pF-M4G). To corroborate this find-
ing in vitro, we used a toeprinting assay to analyze the formation of
ribosomal initiation complexes on virF mRNA (28). A predomi-
nant toeprint was seen 17 nt downstream of AUG4 and a minor
one 16 nt downstream of AUG1 (Fig. 2C), in line with our in vivo
results (Fig. 2A and B). Additional bands downstream of position
17 of AUG4 implicated possible 30S binding-driven structure
changes resulting in reverse transcription pauses. In conclusion,
translation of VirF30 initiates predominantly at ATG4. Through-
out the remainder of this paper, codon positions are accordingly
renumbered, with ATG4 as codon 1.
While searching for a VirF21 translation start site, we noticed
an in-frameATGcodonwithin virF at position 311 to 313 (relative
to1 of virF) (Fig. 1B), consistent with translation of the minor
form of VirF. To validate ATG81 (formerly ATG84) as the start
codon for VirF21, two mutations were introduced into virF, gen-
erating a codon change and a frameshift, respectively. To mutate
ATG81 to a different codon that would retain VirF30 function, we
changed the ATG (mRNA position 311 to 313) to CTG (Met to
Leu; pF-M81L) (Fig. 3A) or toATC (Met to Ile; pF-M81I).Neither
mutation should affect VirF30 translation but should abolish in-
dependent translation of VirF21. Both mutant VirF30 proteins
were tested for activated expression of virB in a virF-defective
S. flexneri strain (M90TFd) (see Table S1 in the supplemental
material) carrying plasmids expressing wt VirF, VirFM81L, or
VirFM81I. VirFM81L but not VirFM81I activated virB to a level com-
parable to wt (see Fig. S1 in the supplemental material). Thus, the
substitution in VirFM81I impairs VirF30 functionality, and there-
fore only pF-M81L was used in subsequent experiments. More-
over, the exclusive expression of VirF30 upon Met¡ Leu substi-
tution (Fig. 3B) identified ATG81 as the start codon for VirF21.
To uncouple the translation of VirF30 and VirF21, we inserted a
FIG 1 Detection of two VirF protein variants. (A) Western blot analysis with
anti-FLAG antibody of whole-cell extracts of S. flexneri M90T carrying virF-
3FLAG. Two forms are indicated, VirF30 and VirF21. (B) Schematic organi-
zation of the virF gene of Shigella. Themethionine (M) codons relevant for this
study are highlighted. The transcription start site (1) was identified previ-
ously (5).
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single G between positions 207 and 208 of virF to create a
frameshift (pF-FS) into two stop codons (UGAandUAG,243 to
249), upstream of ATG81 of VirF21 (Fig. 3A). The wt virF gene
and its M81L (substitution) and frameshift mutant variants were
FLAG tagged, resulting in plasmids pGEM-6504-FT, pGEM-
M81L-FT, and pGEM-FS-FT. Western blot analysis of total pro-
tein from E. coli cells showed that only VirF30 is translated from
pGEM-M81L-FT and onlyVirF21 is translated frompGEM-FS-FT
(Fig. 3B). Western blotting assays with cells with untagged plas-
mids confirmed this result (see Fig. S2 in the supplemental mate-
rial). Since premature termination of frameshifted virF only abol-
ished the synthesis of VirF30 and not that of VirF21, both proteins
are independently translated.
The relative expression of the two VirF forms was further an-
alyzed by translational lacZ fusions. Four virF-lacZ fusions en-
abled us tomonitor translation of VirF21 (pRS-M4G and pRS-FS)
and VirF30 (pRS-M81L), in comparison to total wt virF mRNA
translation (pRS-6504). The -galactosidase levels from pRS-
M4G and pRS-FS were about 3-fold lower than those from pRS-
6504 and pRS-M81L, which is congruent with the Western blot
results shown in Fig. 3B; under these experimental conditions,
VirF21 is a minor fraction of the total VirF protein pool.
VirF21 negatively autoregulates the virF gene. What is the
function of the independently translated VirF21? To test whether
VirF21 can activate virulence genes, the promoters of virB and icsA
were transcriptionally fused to lacZ and transferred to the chro-
mosome of the E. coli K-12 strain P90C, generating P90CB and
P90CA, respectively (see Materials and Methods). Activation by
wt VirF30 and VirF21 (pMYSH6504), VirF30 (pF-M81L), and
VirF21 (pF-FS) was monitored in strain P90C B or P90C A.
Figure 4A shows that VirF30 alone (pF-M81L) induced the ex-
pression of both lacZ fusions to a level similar to that in the
presence of bothVirF30 andVirF21 (pMYSH6504).VirF21 alone (pF-
FS) failed to activate (Fig. 4A). Quantitative reverse transcription-
PCR (qRT-PCR) results with the S. flexneri strain M90T Fd (virF
defective) carrying the same three plasmids supported this con-
clusion (Fig. 4B). Thus, a role for VirF21 in the activation of the
virulence cascade of Shigella is ruled out. A qRT-PCR experiment
also confirmed that the previously shown VirF-dependent activa-
tion of some chromosomal heat shock genes (20) cannot be car-
ried out by VirF21 (see Fig. S3 in the supplemental material).
To address putative functions of VirF21, we investigated its role
in positive or negative autoregulation of the virF gene. An E. coli
K-12 strain harboring a PvirF-lacZ fusion (DH10b pvirF-lacZ) was
FIG 2 Identification of the translation start codon of VirF30. (A, left) Schematic of the pFL plasmids used. Plasmids pFL-1A and pFL-4A carry a translational
fusion between the 5=-UTR of virFmRNA after Met1 (pFL-1A) or Met4 (pFL-4A), in frame with lacZ. (Right) pFL-M4G, the Met4 codon, was replaced by Gly
(ATG to GGG). -Galactosidase activities of E. coli strain DH10b carrying the same virF-lacZ plasmids are shown. Strains harboring the pRS414 vector showed
very low -galactosidase activity levels (2 to 4Miller units) relative to the values obtained. Values are averages of three experiments, and standard deviations are
indicated. (B)Western blot with VirF antibodies on extracts fromMG1655 harboring pMYSH6504, a plasmid carrying the wt virF gene of S. flexneri, or pF-M4G
(pMYSH6504with theM4G substitution). The asterisk indicates unspecific cross-hybridizationwith a protein in the extract. (C) Toeprint assay results on the1
virFmRNA (seeMaterials andMethods). The mRNAwas incubated alone (lane 1), with 30S (lane 2), and with 30S and tRNAfMet (lane 3). Toeprints at position
16 fromATG1 and at17 fromATG4 are indicated by a black circle and asterisk, respectively. Sequencing ladders were generatedwith the same 5=-end-labeled
primer.
Leaderless Translation of Short Shigella VirF Protein

















transformed with plasmids that expressed either Ptac promoter-
driven VirF30 (pAC-30) or VirF21 (pAC-21). Figure 5A clearly
shows that VirF21, but not VirF30, strongly repressed virF expres-
sion, and qRT-PCR on the same samples showed corresponding
decreases in lacZmRNA levels in the presence of VirF21 (Fig. 5B).
To validate VirF21-mediated repression of virF transcription in
Shigella, we asked whether increased VirF21 levels would reduce
the expression of the VirF-activated virB gene. qRT-PCR experi-
ments in the virF-defective strainM90TFd expressingVirF30 from
pF-M81L confirmed severely reduced virB transcription upon in-
duction (isopropyl--D-thiogalactopyranoside [IPTG]) of VirF21
(pAC-21) (Fig. 5C). To monitor the VirF21 induction-dependent
effect on the VirF protein level, we introduced pAC-21 in the
S. flexneri strain that contained the 3FLAG virF gene (M90T
F3xFT; see above). This setup permitted us to assess the levels of
VirF21 andVirF30 encoded by pINVby FLAG-tagged antibodies as
a function of increasing levels of untagged VirF21 expressed from
pAC-21 (monitored via a halon anti-VirF antibody). Figure 5D
shows that increasing the VirF21 concentration resulted in a de-
crease in VirF30, confirming that VirF21 negatively autoregulates
virF expression.
In addition, we performed DNase I footprinting by in vitro-
translated VirF21 on both strands of the virF promoter region.
VirF21 was translated in an in vitro system (PureSystem) (see Ma-
terials and Methods), using a PCR-generated DNA template for
virF21-only transcription and translation. VirF21 translation was
verified by Western blotting (see Fig. S4 in the supplemental ma-
terial). Figure 5E indicates that VirF21 binding conferred protec-
tion of the virF promoter region between positions90 and20
on the plus strand and approximate positions60 to10 on the
minus strand and enhanced minus-strand cleavage from about
positions70 to90. This result, together with data from in vivo
experiments (Fig. 5A and B), strongly suggests that the transcrip-
tional repression of virF by VirF21 depends on its direct binding to
the consensus virF promoter elements.
Identification of a VirF21-encoding leaderless mRNA. The
above results showed that two VirF proteins are independently
translated. Whether both are translated from the same mRNA, or
different versions of virF transcripts, was unknown. The possibil-
ity of different mRNAs was suggested by two virF mRNA vari-
ants detected in a Northern blot assay performed with total
RNA from strain M90T Fd complemented with the virF-
encoding pMYSH6504 and with plasmid-free M90T Fd (Fig. 6A).
An 960-nt band (full-length virF mRNA; R1) and an 680-nt
mRNA that might support translation of VirF21 (R2) were visible.
To test whether R2 virFmRNA is transcribed from a virF internal
promoter or generated by processing, virF-lacZ transcriptional
fusions and primer extension (PE) analyses were used. We con-
structed four virF-lacZ fusions starting at positions 70, 145,
205, and 305; all were fused at 405. The -galactosidase
activities clearly indicated the presence of a promoter between
205 and305; truncation up to position305 produced back-
FIG 3 Differential translation of VirF30 and VirF21. (A) Schematic representation of the constructs used to exclusively produce VirF30 or VirF21. Sequences
relevant for the construction of plasmid pF-M81L (M81L substitution) or plasmid pF-FS (insertion of G at position 208) are highlighted. Plasmids are
derivatives of pMYSH6504. (B) Western blot analysis (with anti-FLAG antibody) of extracts of E. coli DH10b carrying pGEM-6504-FT (VirF30 and VirF21),
pGEM-M81L-FT (only VirF30), or pGEM-FS-FT (only VirF21). (C)-Galactosidase activity levels of the virF-lacZ plasmids obtained by fusing a fragment (289
to405) of the virF gene of pMYSH6504 (pRS-6504), pF-M81L (pRS-M81L), pF-M4G (pRS-M4G), pF-FS (pRS-FS), or pF-FS-M81L (pRS-FS-M81L) as the
control, to the promoterless lacZ gene of pRS414. Values are averages of three experiments, and standard deviations are indicated.
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ground values (Fig. 6B). A promoter was indeed predicted by Pro-
moterHunt (29), with consensus10 (CATTAT;298 to303)
and 35 elements (TTGACA; 276 to 289) (Fig. 6C). After
mutagenesis of the10 box [CATTAT to CGTTAT; pRS-F(205
10mut)], we observed a severe reduction (7-fold) in the
-galactosidase level. This new promoter was further delineated
by PE analysis on RNA extracted from E. coli cells harboring the
different virF-lacZ plasmids. This showed 5= ends at positions
309,310 (major band), and311. All three bandswere absent
in the PE on pRS-F(305), while with pRS-F(20510mut) the
309/310 bands were not detected. The weaker band at 311 is
consistent with a shifted10 box (data not shown). Thus, the R2
virF mRNA is transcribed from a second virF promoter, with a
transcription start site at position309/310.
The 5= ends at309 to 311 and the start codon at311 to 313
imply that the R2 mRNA is leaderless (Fig. 6C). To test whether
the llmRNA is VirF21 translation competent, we cloned the se-
quence corresponding to R2mRNA, and also the entire R1mRNA
as a control, downstream of a T7 promoter. To ensure a correct 5=
end of the R2 mRNA in vivo (5= U309 as 1) (Fig. 6C), a ham-
merhead ribozyme sequence downstream of the T7 promoter (see
Fig. S5 in the supplemental material) was introduced to generate
an R2mRNA starting at position309. The plasmids carrying the
R1 or R2 transcripts, pAC-T730-FT (R1; virF 1 to 888) and
pAC-T7-HH-21-FT (R2; virF 309 to 888) also harbored 3=
FLAG tags in virF. Upon IPTG induction, virF mRNA transcrip-
tion from the T7 promoter was induced in E. coli BL21(D3) har-
boring either plasmid. PE analysis verified the expected 5= ends of
both transcripts (Fig. 7A).
VirF21 translation from the leaderless R2 mRNA was tested by
immunoblot analysis on protein extracts after induction. VirF21
was detected in cells carrying pACT7-HH-21-FT, confirming that
R2 is a leaderless translation-proficient mRNA (Fig. 7B, right
panel). Translation of both VirF forms was observed in cells har-
boring pAC-T730-FT (Fig. 7B, left panel). In vitro translation in
the PureSystem (30) was tested on R1 and R2 mRNAs carrying
FLAG tag sequences. Translation products were analyzed with
anti-FLAG antibodies. In agreement with the in vivo results, R1
mRNA supported translation of both VirF forms, whereas the
leaderless R2 transcript only produced VirF21 (Fig. 7C). Further-
more, toeprint experiments on in vitro-transcribed virFR1mRNA
(start, 1) showed a strong RT stop near the 5= end, indicating
initiation complex formation at AUG4 (compare with Fig. 2C). In
contrast, a specific toeprint was observed at position326 for the
llmRNA R2 (start, 309) (Fig. 7D). This toeprint was absent on
R1 mRNA, indicating a strong preference for VirF30 translation
from the full-length mRNA. Together, these results suggest that a
new virF promoter generates a llmRNA variant (R2 mRNA) ded-
icated to the exclusive translation of VirF21.
DISCUSSION
The complex regulatory cascade for activation of the Shigella vir-
ulence genes depends on the VirF protein (7). VirF is at the heart
of the switch from the noninvasive to the invasive phenotype.
Thus, it is not surprising that its expression is triggered by many
environmental signals and that it is controlled at several levels (2,
4, 10, 17). Since its discovery, VirF was known to be present in
three forms that differ in size: 30, 27, and 21 kDa (25). The smaller
forms were ignored as likely degradation products. Here, we re-
port that the VirF 21-kDa form is translated as an independent
polypeptide. Our results address how the VirF21 variant is pro-
duced and suggest an autoregulatory role in virF expression. As a
first step, we identified the translation start sites of VirF30 and
VirF21. Of the threeMet codons among the first four codons of the
predicted virF ORF, only ATG4 was essential for VirF30 transla-
tion (Fig. 1 and 2). Replacement with GGG drastically reduced
VirF, asmonitored byWestern blotting or-galactosidase activity
of virF-lacZ translational fusions (Fig. 2A and B). The identifica-
tion of ATG4 as a start codon was further supported by toeprint
analysis (Fig. 2C). The start codon consistent with the size of
VirF21 is ATG81; accordingly, replacement with CTG blocks
VirF21 production (Fig. 3B).
Interestingly, while the wt virF mRNA is translated into both
VirF30 and VirF21 in vivo, a frameshift mutation upstream of
FIG 4 Functional analysis of VirF30 and VirF21. (A) -Galactosidase activity
of E. coli P90C carrying virB-lacZ and icsA-lacZ transcriptional fusions, trans-
formed with a plasmid expressing VirF30 and VirF21 (pMYSH6504), only
VirF30 (pF-M81L), or only VirF21 (pF-FS). Values are averages of three exper-
iments, with standard deviations indicated. (B) In vivo levels of virB and icsA
mRNA as a function of the two VirF forms, monitored by qRT-PCR in avirF
S. flexneri strain (M90T Fd) transformed with pMYSH6504 (VirF30 and
VirF21), pF-M81L (VirF30), or pF-FS (VirF21). Expression levels were moni-
tored in M90T or M90T Fd as controls. Samples were run in triplicate, and
error bars show the calculated maximum (RQMax) and minimum (RQMin)
levels that represent the standard error of the mean expression level (RQ
value).
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FIG 5 VirF21 autoregulates virF expression. (A) -Galactosidase activity of virF-lacZ fusions in response to increased levels of VirF21 or VirF30. Ectopic
expression of VirF21 orVirF30 was obtained inE. coli pvirF-lacZ strains carrying pAC-21 or pAC-30, respectively. pGIP7, empty vector. Values are averages of three
experiments, and standard deviations indicated. (B) In vivo levels of lacZ mRNA were monitored in the same samples used in the -galactosidase assay
summarized in panel A. Triplicate samples were evaluated, and error bars indicate standard errors of the mean expression levels (RQ values). (C) In vivo levels
of virB mRNA were monitored in the virF S. flexneri strain (M90T Fd) carrying pF-M81L (VirF30) or ectopically expressing VirF21 under IPTG control
(pAC-21). Triplicate samples were evaluated; error bars show standard errors of themean expression levels (RQ values). (D)Western blot analysis of cell extracts
of M90T F3xFT carrying pAC-21, with or without ectopic induction of VirF21. The level of expression of VirF30 was monitored with an anti-FLAG antibody.
VirF21 induction was monitored with an anti-VirF antibody. Asterisks indicate unspecific cross-hybridization with an unknown protein in the extract. (E)
Identification of the VirF21 binding site on the virF promoter based onDNase I footprinting results. Plasmid pMYSH6504 DNA (41) was incubated with 0, 10 or
20 l of in vitro-translated VirF21. The samples were DNase I treated and subsequently analyzed as described in Materials and Methods, using ML-U30 and
ML-U29 as primers. Sequencing ladders were generated with the same 5=-end-labeled plus- or minus-strand-specific primers. The VirF21-protected site is
indicated by vertical black lines and shown by shading on both strands of the virF promoter sequence.
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ATG81 affects only the production of VirF30, and not that of
VirF21. Thus, the two forms are independently translated
(Fig. 3B); consequently, a derivative with either the FS mutation
or the M81L substitution gives only VirF21 or only VirF30, respec-
tively. -Galactosidase fusion and immunoblot analyses (Fig. 3C)
showed that the expression level of VirF21 under our experimental
conditions is generally lower than that of VirF30.
VirF21 is clearly not functionally redundantwithVirF30.Unlike
VirF30, it does not restore the expression of VirF-regulated genes
in a virF-defective S. flexnerimutant (Fig. 4). Instead, overexpres-
FIG 6 In vivo analysis of virF transcripts. (A) Northern hybridization of 10 g of total RNA from S. flexneri strain M90TFd, with or without pmysh6504 (virF
wt) and a virF-specific 32P-labeled probe indicated two major mRNA variants. (B) Schematic representation of virF-lacZ transcriptional fusions carrying
truncations of the region upstream of the translational start site of VirF21. The ATG for VirF21 is indicated as a reference, and the putative promoter is depicted
by an arrow. The -galactosidase activities of the virF-lacZ fusion strains were determined. Values reported are in Miller units and represent the averages 
standard deviations of five independent experiments. (C) Schematic representation of the new virF promoter. The positions of the35 and10 elements are
indicated, and the mutated10 box (10mut) is shown above. PE analysis results are shown for total RNA extracted from E. coli cells carrying the indicated
plasmids. Three 5= ends at position309,310, and311 are indicated by asterisks. The10 mutation shows only a 5= end at311.
FIG 7 Analysis of VirF21 translation from the virF R2 transcript. (A) Primer extension analysis of total RNA from BL21(DE3) cells carrying pAC-T730FT or
pACT7-HH-21-FT with or without induction using IPTG. The arrowhead indicates the position of hammerhead cleavage. (B) Western blot analysis of total
protein extracts from strain BL21(DE3) cells carrying pAC-T730FT or pACT7-HH-21-FT, with or without induction by IPTG. Shown is translation of both
VirF30 and VirF21 in the presence of pACT7-HH-21-FT or of only VirF21 in the presence of pACT7-HH-21-FT. (C) In vitro translation of virF R1-3XFT (start,
 1) and R2-3XFT (start, 309)mRNAs. Both VirF30 andVirF21 were translated from virFR1-3XFT, but only VirF21 was translated from virFR2-3XFTmRNA.
Asterisk, unspecific cross-hybridization with a protein in the extract. In the blot on the right, we included ompFmRNA as an internal canonical, SD-dependent
translation control. (D) Toeprint assay results with1 (full-length) and309 (leaderless) virFmRNAs. ThemRNAs were incubated alone (control; lanes 1 and
4), with 30S (lanes 2 and 5), or with 30S and tRNAfMet (lanes 3 and 6). A specific toeprint was observed on full-lengthmRNA (1) near the 5= end (black circle)
(compare with Fig. 2C). A second toeprint, specific to the llmRNA, is at position 326 (black asterisk). Sequencing ladders were generated with the same
5=-end-labeled primer.
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sion of VirF21 negatively autoregulates virF expression, reducing
intracellular levels of VirF30 and causing reduced virB expression
(Fig. 5B). This negative autoregulation is likely due toVirF21 bind-
ing to the virF promoter, as indicated by the position of a DNase I
footprint (Fig. 5E) which is predicted to interfere with RNA poly-
merase access.
An arrangement based on a smaller protein controlling a larger
one, with both of them encoded by the same gene, applies to Tn5
transposase (31). The form of Tn5 transposase lacking the first
55 amino acids posttranslationally forms nonproductive com-
plexes with transposase, thus blocking its activity at IS50 inverted
repeats (31). Superficially similar in setup, the shorter VirF21 also
lacks a large N-terminal portion of the longer VirF30 protein, but
here, the shorter form alone is sufficient to exert control at the
level of virF transcription (Fig. 5A). Though the known
C-terminalDNA-binding domain is present in bothVirF variants,
our data suggest different DNA recognition preferences. Further
work will test whether N-terminal sequences affect binding prop-
erties of VirF30 and whether protein folding differences in the
shared domain can account for the observed specificity differ-
ences.
Since VirF30 and VirF21 originate from differential translation,
we investigated the virF transcripts in more detail. Long (R1) and
shorter (R2) virF mRNAs of lengths compatible with VirF30 and
VirF21 were detected (Fig. 6A). Evaluation of deletions in the re-
gion upstream of the VirF21 ORF, along with PE analyses, identi-
fied a new gene-internal virF promoter that drives the transcrip-
tion of the virFR2mRNA. In vivo and in vitrodata support that the
leaderless R2 is translated into VirF21; plasmid vectors encoding
R2 (start site,309) support in vivo translation ofVirF21 (Fig. 7B).
Moreover, leaderless translation of VirF21 by R2 also occurs in
vitro (Fig. 7C), and initiation complex formation occurs at the
appropriate position (Fig. 7D).
In recent years, noncanonical translation initiation mecha-
nisms have been reported, including so-called leaderless tran-
scripts, i.e., those lacking a 5=-untranslated region (UTR) and an
SD sequence (32–34). Most leaderless genes identified so far in
E. coli reside in mobile DNA, including , P2, and Tn1721. The
virF gene is also located within an IS-rich region on an extrachro-
mosomal element, the large Shigella/EIEC invasive plasmid (9).
Sequencing data for bacteria and archaea suggest that a leaderless
model may not be uncommon (35, 36).
The mechanisms underlying synthesis and translation of llm-
RNAs are not yet fully understood. Vesper et al. (37) showed that
induction of the MazEF toxin-antitoxin (TA) system in E. coli
produces a leaderless mRNA population and, simultaneously,
specialized “stress” ribosomes with a preference to translate pro-
teins from llmRNAs. The endoribonuclease MazF cleaves single-
strandedmRNAs, sometimes at ACA sequences upstreamof AUG
start codons, generating llmRNA. MazF also cleaves 16S rRNA,
removing the anti-SD sequence required for translation on ca-
nonical mRNAs. Thereby, a subpopulation of ribosomes is gener-
ated for selective translation on llmRNA (37). It is well established
that Shigella bacteria sense and respond to environmental condi-
tions within and outside the host, with corresponding reprogram-
ming of transcription. Since VirF21 modulates the intracellular
level of VirF, this suggests that the transcription of the leaderless
R2 mRNA could occur under conditions where the activation of
the virulence program is undesirable. A possible coupling between
stress conditions that might promote changes in R2 virF mRNA
transcription and/or preferential translation of leaderless R2
mRNA and effects on virulence gene regulation is an exciting pos-
sibility that we intend to pursue. In particular, the environmental
cues that may regulate transcription of the shorter virF mRNA,
and the translation of VirF21 from the llmRNA under stress and
infection-relevant conditions, will be addressed. In summary, this
study has addednew, entirely unexpected elements to the complex
regulation of the Shigella virulence system and of its major regu-
lator, the VirF protein.
MATERIALS AND METHODS
Oligodeoxyribonucleotides. Oligodeoxynucleotides used in this study
(see Table S1 in the supplemental material) were purchased from Meta-
bion.
Bacterial strains and general methods. Strains used in this study are
listed in Table S2 in the supplemental material. Cloning was performed
wtih strain DH10b. E. coli strain P90CB was obtained by transferring a
PvirB-lacZ fusion fromplasmid pRS415 via homologous recombination to
the lac transducing phage RS45 and then integration (38) into the the 
att site of E. coli P90C. P90CA was previously described (see Table S2).
Strains M90T-F3xFT and M90T Fd(virF) were previously constructed
(21).
Bacteria were grown aerobically in LB medium at 37°C. Antibiotics
and chemicals were used at the following concentrations: ampicillin,
50 g/ml; chloramphenicol, 25 g/ml; kanamycin, 30 g/ml; streptomy-
cin, 10 g/ml; tetracycline, 5 g/ml; 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside, 20 mg/ml. -Galactosidase assays were performed as
described elsewhere (39). Reported values represent the means of at least
three separate measurements. DNA isolation, PCR, restriction digests,
cloning, and other DNA manipulation methods were performed as de-
scribed previously (39). Plasmids are listed in Table S3 in the supplemen-
tal material. In addition, plasmid constructions are detailed in Text S1 in
the supplemental material.
Analysis of virF mRNA. S. flexneri M90T Fd (virF) (Table S2) cells
with orwithout pMYSH6504were grown in LB broth at 37°C to an optical
density at 600 nm of 0.4 to 0.5. Total RNA extraction and Northern blot
assays with an -32P-labeled virF-specific probe were performed as de-
scribed elsewhere (21). Loading controls entailed rRNA staining. Radio-
activity was quantified using a Typhoon 9200 instrument (GE Health-
care).
qRT-PCR was performed using Power SYBR green PCR master mix
on a 7300 real-time PCR system (Applied Biosystems) as described previ-
ously (19). The levels of virB, icsA, and lacZ transcripts were analyzed
using the 2CT (cycle threshhold [CT]) method (40), and results are
reported that the fold increase relative to the reference. Primers for mdh
(endogenous control) and for virB, icsA, and lacZ transcripts were de-
signed by using Primer Express software v2.0 and validated. The following
oligonucleotides were used (see Table S1 in the supplemental material):
mdhQF/mdhQR, virBQF/virBQR, icsAQL/icsAQR, and lacZQF/lacZQR.
Primer extensions. Total RNA from exponentially growing plasmid-
carrying E. coli strains was extracted (41). Total RNA (10 to 20 g) was
hybridized with 5=-32P-labeled ML-512 and ML-1314 primers. Reverse
transcription experiments were done at 42°C using the reverse transcrip-
tase ImProm-II (Promega). Reaction products were analyzed on an 8%
polyacrylamide gel in parallel with sequencing reaction products obtained
using the same primers.
DNase I footprinting. Supercoiled plasmid pMYSH6504 (42)
(200 ng/sample) was preincubated for 20 min at room temperature with
the indicated volumes of the translation mixture, which contained VirF21
or control (no-template) PureSystem reagent in 30 l of binding buffer
(40 mMTris-HCl [pH 8.0], 50 mMKCl, 10 mMMg-acetate, and 0.5 mM
dithiothreitol). The DNA-protein complex was incubated with 1 U of
DNase I for 40 s. After stopping the reaction, the DNA was precipitated
and separately analyzed by primer extension on either DNA strand with
3 pmol of 5=-end-labeled primers ML-U30 or ML-U29 as described pre-
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viously (14). The extension products and corresponding sequencing re-
actions were run on 7% sequencing gels and then fixed for 5 min (10%
ethanol–6% acetic acid) and dried. Signals were detected using a phos-
phorimager screen.
Immunodetection of VirF protein. Western blot assays were carried
out as described in reference 21. Incubation with primary antibodies
(polyclonal halon anti-VirF, anti-FLAG [Sigma F1804]) was at 4°C in
phosphate-buffered saline–Tween (PBS-T) containing 2% dried skim
milk.Membraneswerewashed and incubated at room temperature for 1 h
with a secondary anti-rabbit (1:10,000) or anti-mouse (1:5,000) horserad-
ish peroxidase-conjugated antibody in PBS-T. After washing with PBS-T,
membranes were developed for 5 min for enhanced chemiluminescence
and visualized on a ChemiDoc XRS system.
RNA in vitro transcription. The virF-3XFT mRNAs R1 and R2 were
transcribed for in vitro translation and toeprint assays. For virF mRNA
R1-3XFT (start,1), DNA templates contained a T7 promoter (PCRwith
primersML-U1/ML-982). For virFmRNAR2-3XFT (start,309), a frag-
ment with a T7 promoter and a hammerhead ribozyme sequence in front
of the virF sequencewas produced by PCR (primersML-U20/ML-982) on
pAC-T7-HH-21-FT as the template (for the hammerhead sequence,
Fig. S5 in the supplemental material). DNA templates were in vitro tran-
scribed as described in reference 43. To obtain virF R2-3XFT, an addi-
tional ribozyme self-cleavage step was performed after in vitro transcrip-
tion according methods described previously (44).
Toeprint assay. Toeprint assays were performed as in reference 45.
Aliquots of 0.2 pmol of unlabeled virF-3xft mRNAs R1 and R2 were an-
nealed with 0.5 pmol 5=-end-labeledML-U25 orML-U26 primer in water
at 95°C for 1min and chilled on ice for 2min. After addition of renaturing
buffer (20 mM Tris-HCl [pH 7.5], 20 mM MgCl2, 100 mM NH4Cl) and
incubation for 10 min at 37°C, 2 pmol of 30S ribosomal subunits was
added. After 15 min, 4 pmol of tRNA-fMet was added, and incubation
continued for 20 min before cDNA synthesis with avian myeloblastosis
virus reverse transcriptase (7.5 U; Invitrogen) and deoxynucleoside
triphosphates (100 nM). Reactions were stopped by phenol-chloroform-
isoamyl alcohol extraction followed by ethanol precipitation. The cDNAs
and sequencing reactions were run on 8%denaturing polyacrylamide gels
that were fixed for 5 min (10% ethanol–6% acetic acid) and dried for 1 h
at 80°C. Signals were detected using a phoshorimager screen.
In vitro translation. To generate VirF21 for DNase I footprinting,
500 ng of a PCR product containing a T7 promoter and the virF21 coding
sequence was used as the template in the PureSystem Express (New Eng-
land BioLabs [NEB]) transcription-translation system at 37°C for 4 h.
VirF21 translation was analyzed by immunoblotting using anti-VirF anti-
bodies (see Fig. S4 in the supplemental material). For the in vitro transla-
tion of different virF mRNAs (Fig. 7C), each purified transcript was de-
natured for 2 min at 95°C, chilled for 1 min on ice, diluted in TMN
(20mMTris-HCl [pH7.5], 10mMMgCl2, 150mMNaCl), and incubated
for 15 min at room temperature. In vitro translation (mRNA at 50 nM)
was performed with the PureSystem Express (NEB) translation system at
37°C. Translation products were analyzed by immunoblotting with anti-
FLAG antibodies.
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